NASDAQ:ALXN - Alexion Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $152.96
  • Forecasted Upside: -3.03 %
  • Number of Analysts: 27
  • Breakdown:
  • 0 Sell Ratings
  • 16 Hold Ratings
  • 10 Buy Ratings
  • 1 Strong Buy Ratings
$157.74
▼ -0.97 (-0.61%)
1 month | 3 months | 12 months
Get New Alexion Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALXN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALXN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$152.96
▼ -3.03% Downside Potential
This price target is based on 27 analysts offering 12 month price targets for Alexion Pharmaceuticals in the last 3 months. The average price target is $152.96, with a high forecast of $200.00 and a low forecast of $73.00. The average price target represents a -3.03% upside from the last price of $157.74.
Hold
The current consensus among 27 contributing investment analysts is to hold stock in Alexion Pharmaceuticals. This rating has held steady since November 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 9 hold ratings
  • 0 sell ratings
7/30/2019
  • 0 strong buy ratings
  • 6 buy ratings
  • 12 hold ratings
  • 0 sell ratings
10/28/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 11 hold ratings
  • 0 sell ratings
1/26/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 12 hold ratings
  • 0 sell ratings
4/25/2020
  • 1 strong buy ratings
  • 11 buy ratings
  • 12 hold ratings
  • 0 sell ratings
7/24/2020
  • 1 strong buy ratings
  • 9 buy ratings
  • 12 hold ratings
  • 0 sell ratings
10/22/2020
  • 1 strong buy ratings
  • 10 buy ratings
  • 16 hold ratings
  • 0 sell ratings
12/21/2020
  • 1 strong buy ratings
  • 10 buy ratings
  • 16 hold ratings
  • 0 sell ratings
1/20/2021

Latest Recommendations

  • 1 strong buy ratings
  • 10 buy ratings
  • 16 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/8/2021Raymond JamesDowngradeOutperform ➝ Market PerformLow
i
12/16/2020TruistDowngradeBuy ➝ Hold$155.00 ➝ $175.00Medium
i
12/15/2020Smith Barney CitigroupDowngradeBuy ➝ Neutral$175.00Low
i
12/15/2020Roth CapitalBoost Price Target$50.00 ➝ $73.00Low
i
12/15/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellReiterated RatingBuy ➝ Neutral$175.00Low
i
12/14/2020SVB LeerinkBoost Price TargetOutperform$159.00 ➝ $200.00High
i
12/14/2020Robert W. BairdDowngradeOutperform ➝ Neutral$140.00 ➝ $175.00High
i
12/14/2020WedbushDowngradeOutperform ➝ Neutral$175.00High
i
12/14/2020Royal Bank of CanadaBoost Price TargetOutperform$139.00 ➝ $175.00High
i
12/14/2020BMO Capital MarketsDowngradeOutperform ➝ Market Perform$152.00 ➝ $175.00High
i
12/14/2020Credit Suisse GroupDowngradeOutperform ➝ Neutral$147.00 ➝ $194.00High
i
11/19/2020Sanford C. BernsteinInitiated CoverageMarket Perform$148.00Low
i
11/5/2020Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target$145.00 ➝ $157.00Low
i
11/5/2020Smith Barney CitigroupBoost Price Target$145.00 ➝ $157.00Low
i
11/5/2020Royal Bank of CanadaReiterated RatingBuyMedium
i
10/30/2020Svb LeerinkLower Price TargetOverweight ➝ Outperform$163.00 ➝ $159.00Low
i
10/30/2020SVB LeerinkBoost Price TargetOutperform$159.00 ➝ $163.00Medium
i
10/30/2020Morgan StanleyLower Price TargetEqual Weight$121.00 ➝ $119.00Medium
i
10/29/2020Piper SandlerBoost Price TargetOverweight$175.00 ➝ $179.00Medium
i
10/28/2020UBS GroupInitiated CoverageNeutral$133.00High
i
10/13/2020Morgan StanleyBoost Price TargetEqual Weight$120.00 ➝ $121.00Low
i
10/7/2020Royal Bank of CanadaBoost Price TargetOutperform$136.00 ➝ $139.00High
i
10/7/2020William BlairReiterated RatingHoldHigh
i
Rating by R. Prasad at William Blair
10/6/2020WedbushReiterated RatingOutperform$156.00Low
i
9/1/2020Stifel NicolausLower Price TargetHold$120.00 ➝ $117.00Low
i
7/31/2020Raymond JamesLower Price TargetOutperform$156.00 ➝ $151.00Low
i
7/31/2020SunTrust BanksBoost Price TargetOutperform ➝ Buy$135.00 ➝ $155.00Medium
i
Rating by Robyn Karnauskas at SunTrust Banks, Inc.
7/31/2020SVB LeerinkBoost Price TargetOutperform$159.00 ➝ $163.00Medium
i
7/30/2020William BlairDowngradeOutperform ➝ Market PerformHigh
i
Rating by Raju Prasad at William Blair
7/30/2020OppenheimerReiterated RatingHoldMedium
i
6/1/2020WedbushBoost Price TargetOutperform$120.00 ➝ $138.00Low
i
6/1/2020Credit Suisse GroupBoost Price TargetOutperform$142.00 ➝ $147.00Low
i
Rating by Martin Auster at Credit Suisse Group AG
5/29/2020SVB LeerinkBoost Price TargetOutperform$150.00 ➝ $159.00High
i
5/26/2020Credit Suisse GroupInitiated CoverageBuy$142.00High
i
Rating by Martin Auster at Credit Suisse Group AG
5/8/2020SunTrust BanksLower Price TargetBuy$141.00 ➝ $135.00Low
i
Rating by Robyn Karnauskas at SunTrust Banks, Inc.
5/7/2020BMO Capital MarketsLower Price TargetOutperform$147.00 ➝ $142.00Low
i
5/7/2020SVB LeerinkLower Price TargetOutperform$156.00 ➝ $150.00Low
i
5/7/2020Raymond JamesLower Price TargetOutperform$159.00 ➝ $156.00Low
i
5/7/2020Morgan StanleyBoost Price TargetEqual Weight$116.00 ➝ $120.00Low
i
Rating by Matthew Harrison at Morgan Stanley
5/6/2020CfraLower Price TargetStrong-Buy$165.00 ➝ $159.00Medium
i
5/6/2020NomuraReiterated RatingBuy$133.00Medium
i
5/5/2020William BlairDowngradeOutperform ➝ Market PerformMedium
i
Rating by Raju Prasad at William Blair
4/27/2020Cantor FitzgeraldInitiated CoverageNeutral$121.00High
i
Rating by E. Merle at Cantor Fitzgerald
4/20/2020UBS GroupReiterated RatingReduceHigh
i
4/17/2020JPMorgan Chase & Co.Lower Price TargetOverweight$168.00 ➝ $163.00High
i
4/15/2020Morgan StanleyLower Price TargetEqual Weight$127.00 ➝ $116.00Low
i
Rating by Matthew Harrison at Morgan Stanley
3/17/2020OppenheimerDowngradeOutperform ➝ Market PerformHigh
i
3/12/2020Wolfe ResearchInitiated CoverageOutperform$140.00High
i
3/5/2020Bank of AmericaDowngradeBuy ➝ Neutral$130.00 ➝ $110.00Low
i
2/25/2020SunTrust BanksReiterated RatingBuy$141.00Medium
i
Rating by Robyn Karnauskas at SunTrust Banks, Inc.
2/3/2020Nomura SecuritiesLower Price TargetBuy$165.00 ➝ $133.00Low
i
1/31/2020Robert W. BairdLower Price TargetOutperform$165.00 ➝ $140.00High
i
Rating by Michael Ulz at Robert W. Baird
1/31/2020Royal Bank of CanadaInitiated CoverageOutperform ➝ Positive$135.00Medium
i
Rating by Kennen MacKay at Royal Bank of Canada
1/31/2020Raymond JamesLower Price TargetOutperform$162.00 ➝ $159.00Medium
i
Rating by Steven Seedhouse at Raymond James
1/31/2020SunTrust BanksBoost Price TargetBuy$141.00High
i
1/30/2020CowenReiterated RatingBuy$165.00High
i
Rating by Phil Nadeau at Cowen Inc
1/19/2020JPMorgan Chase & Co.Reiterated RatingBuyLow
i
1/17/2020Morgan StanleyBoost Price TargetEqual Weight$128.00 ➝ $131.00Low
i
Rating by Matthew Harrison at Morgan Stanley
1/15/2020Raymond JamesBoost Price TargetOutperform$162.00Low
i
Rating by Steven Seedhouse at Raymond James
1/14/2020William BlairReiterated RatingBuyMedium
i
Rating by Raju Prasad at William Blair
1/13/2020WedbushReiterated RatingOutperformHigh
i
12/17/2019Morgan StanleyDowngradeOverweight ➝ Equal Weight$170.00 ➝ $128.00Low
i
Rating by Matthew Harrison at Morgan Stanley
12/6/2019William BlairReiterated RatingBuyLow
i
Rating by R. Prasad at William Blair
11/17/2019Evercore ISIReiterated RatingBuy$145.00Low
i
11/12/2019SunTrust BanksInitiated CoverageBuy$125.00Low
i
10/24/2019OppenheimerLower Price Target$165.00 ➝ $150.00Low
i
10/17/2019Bank of AmericaInitiated CoverageBuyLow
i
10/16/2019CowenReiterated RatingBuy$165.00Low
i
10/11/2019Morgan StanleyLower Price TargetOverweight$177.00 ➝ $170.00Low
i
Rating by Matthew Harrison at Morgan Stanley
9/26/2019William BlairInitiated CoverageOutperform ➝ Outperform$146.00High
i
Rating by R. Prasad at William Blair
9/18/2019Royal Bank of CanadaReiterated RatingBuyLow
i
Rating by Kennen MacKay at Royal Bank of Canada
9/12/2019BMO Capital MarketsInitiated CoverageOutperform$149.00Low
i
9/6/2019Piper Jaffray CompaniesSet Price TargetBuy$180.00Low
i
Rating by Christopher Raymond at Piper Jaffray Companies
9/6/2019Credit Suisse GroupLower Price TargetOutperform$154.00 ➝ $146.00High
i
9/3/2019SVB LeerinkSet Price TargetBuy$157.00Low
i
Rating by Geoff Porges at SVB Leerink LLC
8/30/2019Piper Jaffray CompaniesSet Price TargetBuy$180.00Low
i
Rating by Christopher Raymond at Piper Jaffray Companies
8/30/2019CitigroupSet Price TargetBuy$150.00Low
i
Rating by Mohit Bansal at Citigroup Inc.
8/30/2019Stifel NicolausReiterated RatingHoldLow
i
Rating by Paul Matteis at Stifel Nicolaus
8/30/2019Raymond JamesSet Price TargetBuy$168.00Low
i
Rating by Steven Seedhouse at Raymond James
8/30/2019Robert W. BairdSet Price TargetBuy$165.00Low
i
Rating by Michael Ulz at Robert W. Baird
8/22/2019Piper Jaffray CompaniesReiterated RatingBuyLow
i
Rating by Christopher Raymond at Piper Jaffray Companies
8/21/2019Morgan StanleySet Price TargetBuy$177.00N/A
i
Rating by Matthew Harrison at Morgan Stanley
7/31/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$172.00Low
i
7/25/2019Raymond JamesBoost Price TargetOutperform$164.00 ➝ $168.00High
i
Rating by Steven Seedhouse at Raymond James
5/23/2019CitigroupLower Price TargetBuy ➝ Buy$180.00 ➝ $165.00Low
i
5/23/2019The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$142.00Low
i
5/22/2019WedbushInitiated CoverageOutperform ➝ Outperform$173.00Medium
i
Rating by L. Chico at Wedbush
4/26/2019Raymond JamesBoost Price TargetOutperform ➝ Outperform$161.00 ➝ $164.00Low
i
Rating by Steven Seedhouse at Raymond James
4/10/2019Raymond JamesInitiated CoverageOutperform$161.00Medium
i
Rating by Laura Chico at Raymond James
3/27/2019Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$165.00 ➝ $186.00Low
i
3/21/2019GuggenheimReiterated RatingNeutral ➝ Neutral$135.00High
i
Rating by Yatin Suneja at Guggenheim
3/13/2019CowenReiterated RatingBuy$165.00Low
i
2/22/2019GuggenheimInitiated CoverageNeutral ➝ Neutral$135.00Medium
i
2/12/2019Morgan StanleyBoost Price TargetOverweight ➝ Overweight$165.00 ➝ $175.00High
i
1/22/2019Credit Suisse GroupReiterated RatingBuy$156.00Medium
i
Rating by Martin Auster at Credit Suisse Group AG
12/30/2018Raymond JamesReiterated RatingBuyLow
i
Rating by Laura Chico at Raymond James
12/30/2018Credit Suisse GroupSet Price TargetBuy$156.00Low
i
Rating by Martin Auster at Credit Suisse Group AG
12/21/2018Credit Suisse GroupReiterated RatingBuy$156.00Low
i
Rating by Martin Auster at Credit Suisse Group AG
12/21/2018Raymond JamesReiterated RatingBuyHigh
i
Rating by Laura Chico at Raymond James
11/26/2018OppenheimerSet Price TargetBuy$165.00Medium
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
11/14/2018OppenheimerSet Price TargetBuy$165.00Medium
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
11/13/2018Credit Suisse GroupSet Price TargetBuy$156.00Medium
i
Rating by Martin Auster at Credit Suisse Group AG
10/31/2018Credit Suisse GroupSet Price TargetBuy$156.00High
i
Rating by Martin Auster at Credit Suisse Group AG
10/25/2018CitigroupLower Price TargetBuy$195.00 ➝ $190.00Medium
i
10/24/2018SVB LeerinkSet Price TargetBuy$181.00High
i
Rating by Geoff Porges at SVB Leerink LLC
10/15/2018Credit Suisse GroupSet Price TargetBuy$156.00High
i
Rating by Martin Auster at Credit Suisse Group AG
10/11/2018Morgan StanleyBoost Price TargetOverweight$157.00 ➝ $165.00Low
i
9/28/2018BarclaysBoost Price TargetPositive ➝ Overweight$175.00Low
i
9/25/2018Credit Suisse GroupSet Price TargetBuy$156.00Low
i
Rating by Martin Auster at Credit Suisse Group AG
9/25/2018Stifel NicolausBoost Price TargetHold ➝ Hold$130.00 ➝ $136.00Low
i
9/25/2018CitigroupBoost Price TargetBuy ➝ Buy$173.00 ➝ $195.00Low
i
9/24/2018Robert W. BairdSet Price TargetBuy$165.00Medium
i
Rating by Michael Ulz at Robert W. Baird
8/7/2018Stifel NicolausDowngradeBuy ➝ Hold$154.00 ➝ $130.00Low
i
7/27/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$150.00 ➝ $157.00High
i
7/27/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$184.00 ➝ $188.00High
i
7/27/2018Jefferies Financial GroupReiterated RatingHold$123.00High
i
7/26/2018Evercore ISIReiterated RatingOutperform$158.00Medium
i
6/5/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$149.00 ➝ $154.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
4/30/2018CitigroupBoost Price TargetBuy ➝ Buy$170.00 ➝ $173.00Medium
i
4/27/2018Credit Suisse GroupSet Price TargetBuy$149.00Medium
i
Rating by Alethia Young at Credit Suisse Group AG
4/27/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$151.00 ➝ $155.00Low
i
4/23/2018Raymond JamesReiterated RatingBuyLow
i
Rating by Laura Chico at Raymond James
4/12/2018Nomura SecuritiesBoost Price TargetBuy$165.00Low
i
3/16/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$147.00 ➝ $149.00High
i
3/15/2018Nomura SecuritiesBoost Price TargetBuy ➝ Buy$148.00 ➝ $156.00Low
i
3/15/2018Robert W. BairdSet Price TargetBuy$160.00Low
i
Rating by Michael Ulz at Robert W. Baird
3/15/2018Deutsche Bank AktiengesellschaftSet Price TargetBuy$161.00High
i
Rating by Andrew Peters at Deutsche Bank Aktiengesellschaft
3/9/2018CowenReiterated RatingBuy$163.00Low
i
2/12/2018SunTrust BanksSet Price TargetBuy$172.00Medium
i
Rating by Yatin Suneja at SunTrust Banks, Inc.
2/9/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$177.00 ➝ $180.00Low
i
2/9/2018Stifel NicolausReiterated RatingBuy$151.00Medium
i
2/9/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$148.00 ➝ $151.00Low
i
2/9/2018SVB LeerinkLower Price TargetOutperform ➝ Outperform$166.00 ➝ $153.00Low
i
2/9/2018Deutsche Bank AktiengesellschaftSet Price TargetBuy ➝ Buy$163.00 ➝ $161.00Low
i
Rating by Andrew Peters at Deutsche Bank Aktiengesellschaft
2/9/2018CitigroupLower Price TargetBuy ➝ Buy$173.00 ➝ $170.00Low
i
2/5/2018Evercore ISIUpgradeIn-Line ➝ OutperformHigh
i
1/18/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$147.00Medium
i
1/4/2018Raymond JamesReiterated RatingStrong-Buy ➝ Outperform$178.00 ➝ $130.00Medium
i
1/4/2018UBS GroupDowngradeStrong-Buy ➝ OutperformMedium
i
12/18/2017Robert W. BairdUpgradeNeutral ➝ Outperform$150.00Medium
i
12/12/2017Credit Suisse GroupReiterated RatingBuy$166.00Low
i
Rating by Alethia Young at Credit Suisse Group AG
12/6/2017SVB LeerinkReiterated RatingBuy$169.00Low
i
10/24/2017Royal Bank of CanadaBoost Price Target$166.00N/A
i
10/24/2017Stifel NicolausLower Price TargetBuy$165.00 ➝ $159.00N/A
i
10/23/2017Piper Jaffray CompaniesReiterated RatingOverweight ➝ Overweight$170.00N/A
i
9/25/2017SVB LeerinkReiterated RatingBuy$182.00Low
i
Rating by Geoff Porges at SVB Leerink LLC
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$161.00Medium
i
Rating by Simos Simeonidis at Royal Bank of Canada
9/13/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy ➝ Buy$153.00 ➝ $158.00Low
i
9/13/2017SVB LeerinkReiterated RatingOutperform ➝ Outperform$170.00 ➝ $182.00Medium
i
Rating by Geoff Porges at SVB Leerink LLC
9/13/2017SunTrust BanksReiterated RatingBuy$170.00 ➝ $180.00Medium
i
9/13/2017BMO Capital MarketsReiterated RatingOutperform$168.00 ➝ $173.00Medium
i
9/5/2017JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$163.00 ➝ $175.00Medium
i
Rating by Anupam Rama at JPMorgan Chase & Co.
8/16/2017Evercore ISIInitiated CoverageIn ➝ In-Line$137.00Medium
i
7/28/2017BMO Capital MarketsReiterated RatingOutperform$159.00 ➝ $168.00Low
i
7/28/2017SVB LeerinkBoost Price TargetOutperform$136.00 ➝ $170.00Low
i
Rating by Geoff Porges at SVB Leerink LLC
7/28/2017OppenheimerUpgradeMarket Perform ➝ Outperform$175.00High
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
7/28/2017Morgan StanleyReiterated RatingOverweight$141.00 ➝ $153.00High
i
7/14/2017SunTrust BanksReiterated RatingBuy$165.00Low
i
7/3/2017CowenReiterated RatingOutperform$122.00High
i
6/26/2017UBS GroupReiterated RatingBuy$140.00 ➝ $142.00N/A
i
6/26/2017Robert W. BairdReiterated RatingNeutral$145.00Medium
i
Rating by Michael Ulz at Robert W. Baird
6/22/2017SVB LeerinkReiterated RatingOutperformLow
i
Rating by Geoff Porges at SVB Leerink LLC
6/14/2017OppenheimerReiterated RatingHoldMedium
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
6/14/2017Credit Suisse GroupSet Price TargetBuy$164.00Medium
i
Rating by Alethia Young at Credit Suisse Group AG
6/14/2017JPMorgan Chase & Co.Reiterated RatingHoldLow
i
Rating by Anupam Rama at JPMorgan Chase & Co.
6/14/2017UBS GroupReiterated RatingBuy$108.00N/A
i
6/14/2017Morgan StanleyReiterated RatingOverweight$138.00High
i
6/9/2017The Goldman Sachs GroupReiterated RatingBuy$142.00Low
i
6/8/2017Jefferies Financial GroupSet Price TargetHold$120.00Medium
i
Rating by Eun Yang at Jefferies Financial Group Inc.
5/31/2017UBS GroupReiterated RatingBuy$143.00 ➝ $140.00N/A
i
5/25/2017Morgan StanleyUpgradeEqual Weight ➝ Overweight$101.08 ➝ $138.00High
i
Rating by Matthew Harrison at Morgan Stanley
5/25/2017Deutsche Bank AktiengesellschaftLower Price TargetBuy$160.00 ➝ $153.00High
i
Rating by Andrew Peters at Deutsche Bank Aktiengesellschaft
5/24/2017The Goldman Sachs GroupReiterated RatingBuy$158.00High
i
5/24/2017BMO Capital MarketsReiterated RatingOutperform$158.00High
i
5/24/2017Stifel NicolausReiterated RatingBuy$157.00High
i
5/24/2017BarclaysReiterated RatingOverweight$155.00High
i
5/23/2017OppenheimerReiterated RatingHoldMedium
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
5/23/2017SVB LeerinkReiterated RatingBuyMedium
i
Rating by Geoff Porges at SVB Leerink LLC
5/23/2017JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralHigh
i
Rating by Anupam Rama at JPMorgan Chase & Co.
5/9/2017Raymond JamesReiterated RatingStrong-Buy$176.00Low
i
5/9/2017BarclaysReiterated RatingOverweight$155.00Low
i
5/1/2017BMO Capital MarketsReiterated RatingOutperform$158.00High
i
4/28/2017CowenReiterated RatingOutperform$180.00Medium
i
3/30/2017Nomura InstinetReiterated RatingBuy$148.00Low
i
3/29/2017UBS GroupInitiated CoverageBuy ➝ Buy$138.00N/A
i
3/27/2017Royal Bank of CanadaReiterated RatingOutperform$177.00Low
i
3/20/2017SVB LeerinkReiterated RatingOutperformLow
i
Rating by Geoff Porges at SVB Leerink LLC
3/13/2017SVB LeerinkSet Price TargetBuy$208.00Low
i
Rating by Geoff Porges at SVB Leerink LLC
3/1/2017Nomura InstinetInitiated CoverageBuy ➝ Buy$148.00N/A
i
3/1/2017Nomura SecuritiesInitiated CoverageBuyN/A
i
2/19/2017BMO Capital MarketsReiterated RatingOutperform$166.00 ➝ $158.00N/A
i
2/17/2017Royal Bank of CanadaLower Price TargetOutperform$187.00 ➝ $177.00N/A
i
Rating by Simos Simeonidis at Royal Bank of Canada
2/17/2017Credit Suisse GroupReiterated RatingBuy$160.00N/A
i
Rating by Alethia Young at Credit Suisse Group AG
2/16/2017OppenheimerReiterated RatingHoldN/A
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
2/16/2017CowenReiterated RatingBuyN/A
i
2/8/2017OppenheimerInitiated CoverageHoldN/A
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
2/7/2017JPMorgan Chase & Co.Set Price TargetBuy$170.00N/A
i
Rating by Anupam Rama at JPMorgan Chase & Co.
1/21/2017Royal Bank of CanadaSet Price TargetBuy$187.00N/A
i
Rating by Simos Simeonidis at Royal Bank of Canada
1/12/2017BMO Capital MarketsReiterated RatingOutperformN/A
i
1/9/2017Royal Bank of CanadaReiterated RatingOutperform$187.00N/A
i
Rating by Simos Simeonidis at Royal Bank of Canada
1/7/2017Robert W. BairdReiterated RatingNeutral$145.00N/A
i
Rating by Michael Ulz at Robert W. Baird
1/6/2017Piper Jaffray CompaniesReiterated RatingBuy$176.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
1/5/2017Robert W. BairdUpgradeHoldN/A
i
Rating by Michael Ulz at Robert W. Baird
12/25/2016OppenheimerReiterated RatingHoldN/A
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
12/25/2016SVB LeerinkSet Price TargetBuy$211.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
12/25/2016Jefferies Financial GroupSet Price TargetHold$120.00N/A
i
Rating by Eun Yang at Jefferies Financial Group Inc.
12/23/2016Deutsche Bank AktiengesellschaftReiterated RatingBuy$164.00 ➝ $160.00N/A
i
12/23/2016SVB LeerinkReiterated RatingOutperformN/A
i
Rating by Geoff Porges at SVB Leerink LLC
12/23/2016BMO Capital MarketsReiterated RatingOutperform$171.00N/A
i
12/23/2016Robert W. BairdReiterated RatingNeutral$145.00N/A
i
12/23/2016Piper Jaffray CompaniesReiterated RatingBuy$176.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
12/22/2016Royal Bank of CanadaSet Price TargetOutperform$188.00 ➝ $187.00N/A
i
Rating by Simos Simeonidis at Royal Bank of Canada
12/22/2016Royal Bank of CanadaLower Price TargetOutperform$188.00 ➝ $187.00N/A
i
12/20/2016Credit Suisse GroupSet Price TargetBuy$160.00N/A
i
Rating by Alethia Young at Credit Suisse Group AG
12/16/2016Credit Suisse GroupReiterated RatingOutperform$165.00N/A
i
Rating by Alethia Young at Credit Suisse Group AG
12/15/2016SVB LeerinkReiterated RatingOutperform$211.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
12/15/2016OppenheimerInitiated CoverageMarket PerformN/A
i
12/13/2016Robert W. BairdReiterated RatingNeutral$145.00N/A
i
12/13/2016WedbushReiterated RatingNeutral$135.00N/A
i
Rating by Heather Behanna at Wedbush
12/13/2016Royal Bank of CanadaReiterated RatingOverweightN/A
i
Rating by Simos Simeonidis at Royal Bank of Canada
12/13/2016Morgan StanleyDowngradeOverweight ➝ Equal WeightN/A
i
12/12/2016Piper Jaffray CompaniesSet Price TargetBuy$176.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
12/12/2016JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
Rating by Anupam Rama at JPMorgan Chase & Co.
12/12/2016Royal Bank of CanadaSet Price TargetBuy$188.00N/A
i
Rating by Simos Simeonidis at Royal Bank of Canada
12/12/2016Jefferies Financial GroupSet Price TargetHold$120.00N/A
i
Rating by Eun Yang at Jefferies Financial Group Inc.
12/12/2016CowenReiterated RatingBuy$180.00N/A
i
Rating by Eric Schmidt at Cowen Inc
12/7/2016BMO Capital MarketsReiterated RatingOutperform$171.00N/A
i
12/6/2016Robert W. BairdReiterated RatingNeutral$145.00N/A
i
Rating by Michael Ulz at Robert W. Baird
12/5/2016WedbushReiterated RatingNeutral$135.00N/A
i
Rating by Heather Behanna at Wedbush
11/30/2016SVB LeerinkReiterated RatingOutperform$211.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
11/30/2016(FBRC)Reiterated RatingMarket Perform$130.00N/A
i
Rating by Christopher James at (FBRC)
11/29/2016BarclaysUpgradeEqual Weight ➝ Overweight$150.00 ➝ $155.00N/A
i
11/14/2016(FBRC)Reiterated RatingHoldN/A
i
Rating by Christopher James at (FBRC)
11/14/2016Piper Jaffray CompaniesSet Price TargetBuy$176.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
11/11/2016JPMorgan Chase & Co.Reiterated RatingOverweightN/A
i
11/10/2016The Goldman Sachs GroupReiterated RatingBuy$158.00N/A
i
11/10/2016WedbushReiterated RatingNeutral$135.00N/A
i
Rating by Heather Behanna at Wedbush
11/7/2016SVB LeerinkReiterated RatingBuy$211.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
11/7/2016Credit Suisse GroupReiterated RatingBuy$165.00N/A
i
Rating by Alethia Young at Credit Suisse Group AG
11/6/2016Piper Jaffray CompaniesSet Price TargetBuy$176.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
11/3/2016Deutsche Bank AktiengesellschaftInitiated CoverageBuy$164.00N/A
i
10/28/2016WedbushBoost Price TargetNeutral$132.00 ➝ $135.00N/A
i
10/28/2016The Goldman Sachs GroupUpgradeNeutral ➝ Buy$158.00N/A
i
10/28/2016(FBRC)UpgradeUnderperform ➝ Market Perform$130.00N/A
i
Rating by Christopher James at (FBRC)
10/7/2016(FBRC)Reiterated RatingSellN/A
i
Rating by christopher james at (FBRC)
10/4/2016Brean CapitalInitiated CoverageBuy$221.00N/A
i
Rating by Jonathan Aschoff at Brean Capital
9/26/2016SVB LeerinkBoost Price TargetOutperform$210.00 ➝ $211.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
9/23/2016Jefferies Financial GroupLower Price TargetHold$140.00 ➝ $120.00N/A
i
Rating by Eun Yang at Jefferies Financial Group Inc.
9/22/2016WedbushInitiated CoverageNeutral$132.00N/A
i
9/22/2016CowenReiterated RatingBuyN/A
i
Rating by Eric Schmidt at Cowen Inc
9/20/2016CitigroupBoost Price TargetBuy$154.00 ➝ $155.00N/A
i
Rating by Robyn Karnauskas at Citigroup Inc.
9/15/2016(FBRC)Initiated CoverageUnderperformN/A
i
8/16/2016Piper Jaffray CompaniesReiterated RatingOverweight$185.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
8/9/2016Jefferies Financial GroupReiterated RatingHoldN/A
i
Rating by Eun Yang at Jefferies Financial Group Inc.
7/29/2016Brean CapitalReiterated RatingBuy$221.00N/A
i
Rating by Jonathan Aschoff at Brean Capital
7/29/2016BarclaysLower Price TargetEqual Weight$165.00 ➝ $150.00N/A
i
7/29/2016Stifel NicolausLower Price TargetBuy$195.00 ➝ $182.00N/A
i
7/25/2016Jefferies Financial GroupReiterated RatingHold$159.00 ➝ $140.00N/A
i
Rating by Eun Yang at Jefferies Financial Group Inc.
7/17/2016SVB LeerinkReiterated RatingBuy$200.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
7/13/2016SunTrust BanksLower Price TargetBuy$220.00 ➝ $197.00N/A
i
7/12/2016Royal Bank of CanadaInitiated CoverageOutperform$188.00N/A
i
7/11/2016Credit Suisse GroupUpgradeNeutral ➝ Outperform$186.00 ➝ $165.00N/A
i
Rating by Alethia Young at Credit Suisse Group AG
7/9/2016Credit Suisse GroupUpgradeNeutral ➝ OutperformN/A
i
Rating by Alethia Young at Credit Suisse Group AG
7/8/2016SVB LeerinkReiterated RatingBuy$200.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
7/7/2016Piper Jaffray CompaniesReiterated RatingBuyN/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
6/29/2016CowenReiterated RatingBuyN/A
i
Rating by Sharon Stein at Cowen Inc
6/29/2016Morgan StanleyReiterated RatingOverweightN/A
i
Rating by Matthew Harrison at Morgan Stanley
6/27/2016CitigroupUpgradeNeutral ➝ Buy$154.00N/A
i
Rating by Robyn Karnauskas at Citigroup Inc.
6/26/2016Piper Jaffray CompaniesReiterated RatingBuyN/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
6/17/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Geoff Porges at SVB Leerink LLC
6/13/2016Robert W. BairdReiterated RatingNeutral$145.00N/A
i
Rating by Brian Skorney at Robert W. Baird
6/8/2016CowenReiterated RatingBuyN/A
i
Rating by Eric Schmidt at Cowen Inc
6/7/2016BarclaysLower Price TargetEqual Weight$180.00 ➝ $165.00N/A
i
6/7/2016CitigroupReiterated RatingHoldN/A
i
Rating by Robyn Karnauskas at Citigroup Inc.
6/7/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Geoff Porges at SVB Leerink LLC
6/7/2016OppenheimerReiterated RatingBuy$228.00 ➝ $221.00N/A
i
Rating by Christopher Marai at Oppenheimer Holdings Inc.
6/7/2016Brean CapitalReiterated RatingBuyN/A
i
Rating by Jonathan Aschoff at Brean Capital
6/7/2016BMO Capital MarketsReiterated RatingBuy$168.00 ➝ $160.00N/A
i
Rating by Ian Somaiya at BMO Capital Markets
6/7/2016Morgan StanleyReiterated RatingOverweight$203.00 ➝ $189.00N/A
i
Rating by Matthew Harrison at Morgan Stanley
6/6/2016Piper Jaffray CompaniesReiterated RatingBuy$212.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
6/6/2016Credit Suisse GroupReiterated RatingHold$195.00 ➝ $186.00N/A
i
Rating by Alethia Young at Credit Suisse Group AG
6/6/2016Bank of AmericaReiterated RatingBuyN/A
i
Rating by Ying Huang at Bank of America Co.
5/31/2016OppenheimerReiterated RatingOutperform$228.00N/A
i
Rating by Christopher Marai at Oppenheimer Holdings Inc.
5/29/2016Jefferies Financial GroupReiterated RatingHoldN/A
i
Rating by Eun Yang at Jefferies Financial Group Inc.
5/12/2016SVB LeerinkReiterated RatingBuy$200.00 ➝ $210.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
5/9/2016BarclaysBoost Price TargetEqual Weight$175.00 ➝ $180.00N/A
i
4/30/2016Morgan StanleyReiterated RatingBuyN/A
i
Rating by Matthew Harrison at Morgan Stanley
4/30/2016BMO Capital MarketsDowngradeBuyN/A
i
Rating by Ian Somaiya at BMO Capital Markets
4/30/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Geoff Porges at SVB Leerink LLC
4/29/2016BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$165.00 ➝ $168.00N/A
i
4/28/2016CowenReiterated RatingBuyN/A
i
Rating by Eric Schmidt at Cowen Inc
4/28/2016Brean CapitalReiterated RatingBuyN/A
i
Rating by Jonathan Aschoff at Brean Capital
4/28/2016Piper Jaffray CompaniesReiterated RatingBuyN/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
4/26/2016OppenheimerReiterated RatingOutperform$228.00N/A
i
Rating by Christopher Marai at Oppenheimer Holdings Inc.
4/17/2016CowenReiterated RatingBuyN/A
i
Rating by Eric Schmidt at Cowen Inc
4/10/2016SVB LeerinkReiterated RatingOutperformN/A
i
Rating by Geoff Porges at SVB Leerink LLC
4/8/2016Morgan StanleyBoost Price Target$195.00 ➝ $210.00N/A
i
Rating by Matthew Harrison at Morgan Stanley
4/6/2016BMO Capital MarketsInitiated CoverageMarket Perform$165.00N/A
i
4/5/2016Piper Jaffray CompaniesReiterated RatingBuy$212.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
4/1/2016Morgan StanleyReiterated RatingBuy$195.00N/A
i
Rating by Matthew Harrison at Morgan Stanley
3/19/2016SVB LeerinkReiterated RatingBuy$217.00 ➝ $216.00N/A
i
Rating by Geoff Porges at SVB Leerink LLC
3/7/2016Robert W. BairdDowngradeOutperform ➝ Neutral$221.00 ➝ $170.00N/A
i
3/7/2016CowenReiterated RatingBuy$216.00N/A
i
2/25/2016CitigroupInitiated CoverageNeutral$165.00N/A
i
2/22/2016The Goldman Sachs GroupLower Price Target$186.00 ➝ $168.00N/A
i
2/8/2016Jefferies Financial GroupReiterated RatingHold$190.00 ➝ $165.00N/A
i
2/6/2016SVB LeerinkReiterated RatingOutperform$217.00N/A
i
Rating by H. Liang at SVB Leerink LLC
2/5/2016Bank of AmericaReiterated RatingBuy$227.00 ➝ $204.00N/A
i
2/4/2016Stifel NicolausLower Price TargetBuy$245.00 ➝ $230.00N/A
i
Rating by Stephen Willey at Stifel Nicolaus
2/4/2016JPMorgan Chase & Co.Lower Price Target$225.00 ➝ $185.00N/A
i
2/4/2016Jefferies Financial GroupLower Price TargetHold$190.00 ➝ $165.00N/A
i
2/4/2016The Goldman Sachs GroupLower Price TargetNeutral$199.00 ➝ $186.00N/A
i
2/4/2016UBS GroupLower Price TargetBuy$222.00 ➝ $200.00N/A
i
2/4/2016Brean CapitalReiterated RatingBuy$221.00N/A
i
Rating by Jonathan Aschoff at Brean Capital
2/4/2016Piper Jaffray CompaniesReiterated RatingOverweight$212.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
2/4/2016BarclaysLower Price TargetEqual Weight$202.00 ➝ $175.00N/A
i
(Data available from 1/20/2016 forward)
Alexion Pharmaceuticals logo
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $157.74
$157.26
$159.10

50 Day Range

MA: $147.47
$117.74
$158.71

52 Week Range

Now: $157.74
$72.67
$160.03

Volume

3,540,569 shs

Average Volume

3,364,677 shs

Market Capitalization

$34.52 billion

P/E Ratio

36.86

Dividend Yield

N/A

Beta

1.33

Frequently Asked Questions

What sell-side analysts currently cover shares of Alexion Pharmaceuticals?

The following Wall Street research analysts have issued reports on Alexion Pharmaceuticals in the last twelve months: Bank of America Co., BMO Capital Markets, Cantor Fitzgerald, Cfra, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Cowen Inc, Credit Suisse Group AG, JPMorgan Chase & Co., Morgan Stanley, Nomura, Nomura Securities, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Robert W. Baird, Roth Capital, Royal Bank of Canada, Sanford C. Bernstein, Smith Barney Citigroup, Stifel Nicolaus, SunTrust Banks, Inc., SVB Leerink LLC, TheStreet, Truist, UBS Group AG, Wedbush, William Blair, Wolfe Research, and Zacks Investment Research.

What is the current price target for Alexion Pharmaceuticals?

26 Wall Street analysts have set twelve-month price targets for Alexion Pharmaceuticals in the last year. Their average twelve-month price target is $152.96, suggesting a possible downside of 3.6%. SVB Leerink LLC has the highest price target set, predicting ALXN will reach $200.00 in the next twelve months. Roth Capital has the lowest price target set, forecasting a price of $73.00 for Alexion Pharmaceuticals in the next year.

What is the current consensus analyst rating for Alexion Pharmaceuticals?

Alexion Pharmaceuticals currently has 16 hold ratings, 10 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ALXN, but not buy more shares or sell existing shares.

What other companies compete with Alexion Pharmaceuticals?

How do I contact Alexion Pharmaceuticals' investor relations team?

Alexion Pharmaceuticals' physical mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company's listed phone number is 475-230-2596 and its investor relations email address is investorrelations@alexion.com. The official website for Alexion Pharmaceuticals is www.alexion.com.